MedInCell Stock Rebounds by 2.46% After a 22% Drop Over Three Months
MedInCell's stock price significantly advanced this Monday during trading, reaching 20.84 euros compared to 20.34 euros at last Friday's close. This 2.46% rebound follows a marked correction period, with the stock losing over 22% in the past three months. Meanwhile, the CAC 40 slightly declined by 0.05% during the session, standing at 7,907 points.
MedInCell's stock price this Monday is at 20.84 euros, testing the support zone identified at 20.34 euros, which precisely matches last Friday's closing price. The rebound observed at the beginning of the week originates from this technical floor, in a context where the stock shows an RSI at 32, close to the oversold zone (below 30), indicating a possible short-term excess of selling pressure. The price remains significantly below its 50-day moving average, which is at 24.51 euros, reflecting a downward trend established over recent weeks. The gap of nearly 18% between the current price and this average highlights the magnitude of the recent correction. The most significant resistance lies at 25.02 euros, well above current levels. Although the performance over one year remains positive, at more than 51%, the 22% decline observed over three months weighs on the medium-term momentum.
Key Dates Ahead for Financial Performance
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
Almost there! Check your inbox.
A confirmation email has been sent. Click the link to confirm your subscription.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
The financial calendar for the biotech specializing in long-acting injectable formulation technologies schedules the publication of its annual results for the fiscal year 2025-2026 on June 16th. This deadline will be a major focal point to assess the operational trajectory of the group, particularly the evolution of its revenues from licenses and industrial partnerships. The general assembly is scheduled for September 10, 2026, followed by the publication of the results for the first half of 2026-2027, planned for December 8. It is worth noting that the stock's negative beta of -0.38 indicates a behavior that is decoupled from major indices, which can be explained by the specific growth profile of this healthcare sector stock. During this Monday's session, major capitalizations in the sector showed limited variations: Sanofi gained 0.17% while EssilorLuxottica lost 0.15%.
We are pleased with the company’s growth and momentum.
Total income €14,1 million; Revenues €11,6 million (+35 %); UZEDY® royalties €4,2 million; Operating result €(6,6) million (improved 13 % year-over-year); Net result €(16 078) thousand; Cash and low-risk financial investments €53,5 million (incl. €49,8 million cash and €3,7 million low-risk investments); Net financial debt €17 629 thousand; NDA for Olanzapine LAI submitted to FDA on December 9, 2025; AbbVie partnership advancing with regulatory package expected in 2026.
Risks mentioned
Foreign exchange risk: weakness of USD vs EUR impacted revenues and generated ~€1 million FX losses
Dependency on partner commercialization (Teva) for UZEDY® royalties and sales forecasts
Regulatory risk: approvals (e.g., Olanzapine LAI) and acceptance for review uncertain
Financial volatility linked to fair value revaluation of EIB BSA warrants (non-cash €6,8 million impact)
Opportunities identified
Olanzapine LAI: NDA submitted and potential launch could be a major growth catalyst
UZEDY®: upward revision of 2025 net sales forecast by Teva (from $160 million to $190-200 million)
AbbVie partnership: first program advancing toward first-in-human trials (regulatory package expected 2026)
Gates Foundation financing: new $3 million envelope to advance mdc-STM malaria program
Expanded geographic approvals (Canada, South Korea) supporting broader commercialization
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
